Mark-David Levin

36PUBLICATIONS
183CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTumour immunologyInnate immunityImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (36)

|Oct 02, 2026
First-line ibrutinib-venetoclax in chronic lymphocytic leukemia: GLOW 67-month results and grade 3/4 adverse event-free progression-free survival.

|Sep 18, 2026
A functional prognostic model predicts progression-free survival in patients with relapsed chronic lymphocytic leukemia treated with ibrutinib + venetoclax.

|Sep 16, 2026
Impact of Vincristine Dose Reduction on Outcomes of Patients With Advanced-Stage Diffuse Large B-Cell Lymphoma Treated With R-CHOP.

|Sep 04, 2026
Treatment Patterns, Outcomes and Survival Trends in T-Cell Prolymphocytic Leukemia: A Nationwide Population-Based Study in the Netherlands.

|Mar 30, 2026
Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Moritz Fürstenau, Carsten Utoft Niemann, Sandra Robrecht

|Mar 27, 2026
FDG-PET medullary total tumor volume highlights high-risk patients with newly diagnosed multiple myeloma in CASSIOPEIA trial.

Bastien Jamet, Shamimeh Ahrari, Sonja Zweegman

Pageof 6

Frequent Collaborators

13 joint publications

Arnon P Kater

10 joint publications

Carsten Utoft Niemann

9 joint publications

Peter E Westerweel

7 joint publications

Anton W Langerak